Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $2.42M fell 3.4% year over year, behind the +36.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 13.0% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.

Context

  • Stock-based compensation amounted to 376.2% of revenue in FY2025, up 359.2 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -3.4% toward the trailing-twelve-month pace of +36.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.42M+13.0% QoQ
Last fiscal yearDec 2025
$10.52M+59.8% YoY
LTMMar 2026
$10.44M+36.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.4%——
1 year+59.8%——
3-year CAGR-2.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
10.52M USD
Year-over-year change
+59.8%
4-year CAGR
+8.0%

Stock-Based Compensation vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +36.3% is the 4th highest of 9, against a peer median of +20.8%.
  • Stock-based compensation amounts to 587.9% of revenue for RNAC, versus a peer median of 36.3%.
RNAC Competitors
Stock-Based Compensation for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$15.21M USD———
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$11.86M USD+7.9%+52.0%36.3%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$10.44M USD+36.3%-2.0%587.9%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$6.24M USD+33.6%+18.6%12.2%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.04M USD-48.6%-13.0%—
MDWDMediWound Ltd.LTM Mar 2026$2.91M USD-16.2%+16.9%20.1%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$2.64M USD+336.0%+112.4%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-63.8%——
Peer median (excluding RNAC) —+20.8%+21.7%36.3%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Depreciation & Amortization1.25M1.29M843K1.15M2.96M
Deferred Income Tax2.4M(21.4M)(19M)287K(9.19M)
Stock-Based Compensation7.72M11.19M22.52M6.58M10.52M
Change in Working Capital(48.19M)(60.38M)4.97M(5.79M)(8.06M)
Accounts Receivables(2.69M)3.32M907K7.98M(243K)
Inventory211K920K000
Accounts Payables(219K)92K2.83M(2.93M)1.07M
Other Working Capital(45.5M)(64.71M)1.23M(10.84M)(8.89M)
Other Non-Cash Items2.13M2.29M159.21M51.52M60.14M
Operating Cash Flow(60.38M)(31.63M)(51.16M)(23.67M)(73.94M)
Capital Expenditures(1.09M)(1.2M)(206K)(9.09M)(5.45M)
Acquisitions (Net)006.56M351K0
Purchases of Investments(32.46M)(33.5M)000
Sales of Investments16.4M19.7M28.25M00
Other Investing Activities00000
Investing Cash Flow(17.14M)(15M)34.61M(8.74M)(5.45M)
Debt Repayment00(27.46M)00
Common Stock Issued51.96M38.98M0124.44M(301K)
Common Stock Repurchased00(6.17M)00
Dividends Paid00000
Other Financing Activities939K235K231K3.99M(7.75M)
Financing Cash Flow52.9M39.22M(13.15M)168.43M(8.06M)
Effect of Forex Changes(3K)20K(53K)(21K)45K
Net Change in Cash(24.63M)(7.4M)(29.75M)135.99M(87.41M)
Free Cash Flow(61.47M)(32.83M)(51.37M)(32.77M)(79.4M)

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.